title: Serum TPS versus TPA in Egyptian bladder cancer patients.
abstract: This study included 328 cases (106 with bladder cancer, 152 with non-malignant urinary tract diseases and 70 healthy controls). Serum TPA was determined using the Prolifigen TPA IRMA kit supplied by AB Sangtec Medical, Bromma, Sweden and serum TPS was determined using the TPS IRMA kit supplied by Beki Diagnostics AB, Bromma, Sweden. The results of this study revealed that serum TPA had better sensitivity than serum TPS while no marked difference was found in the false-positivity rates in the non-malignant urinary tract diseases. A correlation coefficient of 0.83 was found between serum TPA and TPS. No relation was found between either TPA or TPS and histopathological stage, grade or association of the tumor with bilharziasis. As regards the histopathological type of the tumor, serum TPS was slightly higher in squamous cell than transitional cell carcinoma but TPA showed no difference. In the follow-up of bladder cancer patients after surgery both TPA and TPS showed an excellent concordance with the clinical state of the patients. In conclusion, TPS does not seem to be an optimal test in Egyptian patients with bladder cancer but serial determinations of one of the two markers can be used in the follow-up of these patients after surgery.
authors.affiliation: Tumor Marker Oncology Research Unit, al-Azhar University, Cairo, Egypt.
authors.forename: A B
authors.initials: AB
authors.lastname: Halim
authors.forename: O
authors.initials: O
authors.lastname: el-Ahmady
authors.forename: S
authors.initials: S
authors.lastname: Hamza
authors.forename: M
authors.initials: M
authors.lastname: Aboul-Ela
authors.forename: P
authors.initials: P
authors.lastname: Oehr
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D004534:Egypt; D000939:Epitopes; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis / Q000276:immunology; D010455:Peptides / Q000097:blood* / Q000276:immunology; D012680:Sensitivity and Specificity; D019396:Tissue Polypeptide Antigen; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000276:immunology / Q000601:surgery
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D000939:Epitopes; D010455:Peptides; D019396:Tissue Polypeptide Antigen